Ep. 306 - Treg Inflection Point; Biotech's Next Big Story; Tax Bill Consequences

Treg-based cell therapies are nearing a clinical proof-of-concept inflection point, but in an environment that has dramatically shifted with the advent of CAR T therapies for autoimmune diseases. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss what these cell therapies need to show to be relevant in the fast-changing I&I world, and which types of indications may best suit the cells’ unique profile. The team also explores the biotech sector’s ongoing struggle to capture the interest of generalist investors, and what the next major theme might be to draw them back. The analysts then break down the key provisions in the recently passed U.S. reconciliation tax bill, highlighting the positive and negative developments, as well as the missed opportunities for the industry. This episode of BioCentury This Week was sponsored by IQVIA Biotech. View full story: https://www.biocentury.com/article/656376 #biotech #biopharma #pharma #lifescience #CellTherapy #TregTherapy #CAR_T 00:01 - Sponsor Message: IQVIA Biotech 01:19 - Treg Inflection Point 10:57 - Biotech"s Next Big Story 22:36 - Tax Bill Consequences To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text